Infection of the normal adult is commonly asymptomatic.
In those cases with clinical manifestations, the most com mon of the symptoms is lymphadenopathy, which may be accompanied by an array of other symptoms, making dif ferential diagnosis difficult. On the other hand, severe to fatal infections do occur in adults immunocompromised by cancer chemotherapy or immunosuppressive treatment and in patients with AIDS. Infections in the immunocompro mised adults are thought to be reactivation of latent acquired infections and usually involve the central nervous system, although involvement of other sites has been reported.
Transplacental transmission of the parasite resulting in congenital toxoplasmosis can occur during the acute acquired maternal infection. The risk of fetal infection is a function of time at which acute maternal infection occurs during gestation. Maternal infections acquired before con ception present very little, if any, risk to the fetus. However, the incidence of congenital toxoplasmosis increases as preg nancy progresses; conversely, the severity of congenital toxoplasmosis is greatest when maternal infection is acquired early during pregnancy. A majority of infants infected in utero are asymptomatic at birth, particularly if maternal infection occurs during the third trimester, with sequelae appearing later in life. Congenital toxoplasmosis results in severe generalized or neurologic disease in about 20-30% of the infants infected in utero; approximately 10% exhibit ocular involvement only, and the remainder (about 70%) are asymptomatic at birth. Subclinical infection may result in premature delivery and subsequent neurologic, intellectual, and audiologic defects. Prospective studies of pregnancies have shown that pre natal diagnosis of infection followed by prenatal therapy reduces the frequency and the severity of congenital toxo plasmosis. Serologic tests can be used to identify those pregnancies at risk; women who are seronegative at the time of diagnosis of pregnancy can be monitored during preg nancy. Seroconversion is indicative of T. gondii infection and establishes gestational age when maternal infection occurred, Serologic tests specific for T. gondii IgM antibodies are useful aids in the diagnosis of both congenital and acute acquired toxoplasmosis. Levels of IgM antibody increase rapidly following acute acquired infections and begin to decline after several months, but can persist at detectable levels for a year or more. Since persisting IgM levels may 2 be detected long after the onset of acquired infection, the use of a single serological test result must be used with caution in those cases when it is critical to establish the time of infection. This applies to the diagnosis of acute T. gondi infection acquired during pregnancy. Determination of the date of infection based solely on the results of detectable IgM antibody to T. gondii is not recommended. That deter mination should include clinical history and previous serology, since low levels of IgM antibody may persist for a year or more. The use of a test to determine a rise in IgG antibody to T. gondii may provide additional information as to the date of infection.
Primary rubella infection in most individuals is typically a mild self-limiting disease characterized by a maculopapu lar rash, fever, malaise, and lymphadenopathy. In pregnant women, primary infection can have serious medical conse quences. In utero infections may severely damage the fetus, particularly if occurring during the first four months of gestation. The congenitally infected infant may exhibit one or more of a variety of defects collectively known as the congenital rubella syndrome (CRS). Among these are low birth weight, cataracts, deafness, congenital heart disease, and mental retardation.
Although rubella does have typical symptomology, the clinical picture can be quite variable. The disease is often difficult or impossible to accurately diagnose from symp toms alone. With the advent of hemagglutination inhibition (HAI) testing laboratories were able to provide serological evidence of recent rubella infection by showing increasing levels of antibody activity between paired acute and conva lescent sera. However, since HAItiters increase rapidly from the date of disease onset, the acute serum must be collected early in order to detect a significant increase in titer when compared to the convalescent serum. In addition, HAI titers increase significantly following both primary infection and reinfection so HAI cannot be used to differentiate between the two. The detection of rubella IgM antibody in a single serum sample was made possible with the use of HAI testing coupled with 2-mercaptoethanol treatment or sucrose den sity gradient fractionation. The ability to detect the IgM class of anti-rubella antibody in a single sample overcomes some of the problems associated with paired sera analysis and provides a clearer serodiagnosis picture.
Asymptomatic reinfection of immune pregnant women, generally believed to be harmless to the fetus, is character ized serologically by a rise in IgG antibody in the absence of detectable IgM antibody. A primary infection is associated with a pronounced IgM antibody response to the rubella virus antigen. IgM antibody reactive with rubella virus antigen has been observed following reinfection; however, the levels are low and not detectable by all IgM assays. In cases of acute primary infection during pregnancy, IgM has been detected 4 to 15 days after appearance of the rash in nearly 100% of the cases. IgM levels begin to decline after 36 to 70 days, and are infrequently detected after 180 days.
Although the clinical utility of rubella IgM detection is usually associated with testing pregnancy women, testing of nonpregnant individuals for IgM antibodies to rubella virus antigen is a useful aid in diagnosis of acute infection.
Rheumatoid factors present in some sera may cause false positive results in IgM assays for T. gondii and rubella. To address this problem, some IgMassay protocols require that all specimens that tested positive be treated with Rheuma toid Factor Neutralization Reagents (RFNR) and retested RFNR comprises a suspension of microparticles coated with human gamma globulin. RFNR absorbs rheumatoid factors 3 because rheumatoid factors have an affinity for the Fc portion of the human IgG molecule. When a rheumatoid factor positive human specimen is incubated with RFNR, rheumatoid factors bind to the coated microparticles, and the bound rheumatoid factors are removed via centrifugation. The treated specimen is then retested with an alternative dilution protocol to compensate for the effect of diluting caused by the RFNR procedure. Upon retest, specimens are not interpreted as positive for the specific IgM antibodies unless those specimens remain positive following adsorp tion with the RFNR.
It would be desirable to eliminate the need for treatment of specimens with RFNR and retesting of specimens that were initially positive.
SUMMARY OF THE INVENTION
This invention provides a method for treating biological samples, e.g. human sera or plasma, suspected of containing rheumatoid factors to eliminate cross-reactivity and false positive assay results in IgM immunoassays that are caused by the presence of rheumatoid factors in these biological samples.
In one aspect of the invention, the method comprises introducing to a solid phase material containing a complex comprising an antibody and a binding member specific for that antibody, e.g., an antigen, a sufficient amount of rheu matoid factor neutralization buffer, which buffer has a pH sufficiently low to cause rheumatoid factors bound to IgG antibodies bound to the solid phase material to reduce their affinity to the IgG antibodies to such an extent that the bond of the rheumatoid factors to the IgG antibodies will break and the rheumatoid factors can be washed away from the solid phase material prior to the detection phase of a diagnostic assay. However, the pH of the rheumatoid factor neutralization buffer must not be so low that the binding of the IgM antibodies, e.g. anti-rubella IgM antibodies or anti-T. gondii IgM antibodies, bound to binding members, e.g., antigens, immobilized on the solid phase material is adversely affected. In this particular aspect, the rheumatoid factor neutralization buffer will typically have a pH below about 6.5. Preferably, the rheumatoid factor neutralization buffer has a pH of from about 3.0 to about 5.5, more preferably from about 3.5 to about 5.0.
In another aspect, the method comprises introducing to a biological sample or to a reagent comprising a solid phase material having a binding member specific for IgM antibod ies immobilized thereon or to both the sample and the reagent a sufficient amount of rheumatoid factor neutraliza tion buffer, which buffer has a pH sufficiently low to cause the pH of resulting reaction mixtures containing rheumatoid factors to be sufficiently low to cause rheumatoid factors in those mixtures to reduce their affinity to IgG antibodies to such an extent that they will not form a complex with IgG antibodies bound to the solid phase material, thereby facili tating the removal of these rheumatoid factors from the mixtures prior to the detection phase of a diagnostic assay. However, the pH of the rheumatoid factor neutralization buffer must not be so low that the binding of the IgM antibodies, e.g., anti-rubella IgM antibodies or anti-T. gondi IgM antibodies, bound to binding members, e.g., antigens, immobilized on the solid phase material will be adversely affected. In this particular aspect, the rheumatoid factor neutralization buffer will typically have a pH no higher than about 6.5. Preferably, the rheumatoid factor neutralization buffer has a pH of from about 3.0 to about 5.5, more preferably from about 3.5 to about 5.0. In either aspect, classes of buffers that are suitable for the method of this invention include ionic, nonionic, and Zwit terionic buffers preferably having a pKa value no higher than about 6.5. Representative examples of buffers that are suit able for the method of this invention include, but are not limited to, acetic acid, citric acid, formic acid, succinic acid, and glycine.
The rheumatoid factor neutralization buffer can be used to eliminate interference from rheumatoid factors in IgM immunoassays in at least one of two ways. In one way, the buffer can be used to treat complexes that are attached to the solid phase material. The buffer breaks the bonds between the rheumatoid factors and IgG antibodies that are bound to the solid phase material and elutes of the rheumatoid factors. In another way, the buffer can be added directly to a sample suspected of containing rheumatoid factors or to a reagent containing a solid phase material having immobi lized thereon a binding member specific for an IgM antibody or to both the sample and the reagent. When the sample is combined with the reagent, the buffer lowers the pH of the mixture containing the sample and the reagent and interferes with the binding of rheumatoid factors with IgG antibodies in the sample that bind to the solid phase material.
The invention is particularly useful for use with auto mated continuous and random access analytical systems, such as that described in U.S. Pat. No. 5.358.691, incorpo rated herein by reference.
This invention minimizes false positive assay results that may arise from the presence of rheumatoid factors in human sera or plasma specimens. A primary benefit of this inven tion is its simplicity and the ability to incorporate this step into the assay protocol of an assay being run on an automated, continuous, and random access analytical sys tem. This invention makes it possible to eliminate the requirement of treating off-line all initially positive speci mens with RFNR and retesting, thereby simplifying the assay procedure and reducing the assay time required to determine the presence of IgM antibodies to T. gondii antigen or rubella virus antigen.
DETALED DESCRIPTION
As used herein, "test sample" or "sample" means a material suspected of containing the analyte. The test sample can be used directly as obtained from the source or following a pretreatment to modify the character of the sample. The test sample can be derived from any biological source, such as a physiological fluid, such as, for example, blood, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, synovial fluid, peritoneal fluid, amniotic fluid, and the like. The test sample can be pretreated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment can involve filtration, distillation, extraction, concentration, inactivation of inter fering components, the addition of reagents, and the like. Other liquid samples besides physiological fluids can be used, such as water, food products, and the like, for the performance of environmental or food production assays. In addition, a solid material suspected of containing the analyte can be used as the test sample. In some instances it may be beneficial to modify a solid test sample to form a liquid medium or to release the analyte.
As used herein, "binding member" means a member of a specific binding pair, i.e., two different molecules where one of the molecules through chemical or physical means spe cifically binds to the second molecule. Such enzymes include glucosidases, galactosidases, phos phatases and peroxidases, such as alkaline phosphatase and horseradish peroxidase, which are used in conjunction with enzyme substrates, such as fluoresce in di(galactopyranoside), nitro blue tetrazolium, 3.5'5.5'-tetranitrobenzidine, 4-methoxy-1-naphthol, 4-chloro-1-naphthol. 4-methylumbelliferyl phosphate, 5-bromo-4-chloro-3-indolyl phosphate, chemiluminescent enzyme substrates, such as the dioxetanes described in WO 88100694 and EP 0-254-051-A2, and derivatives and ana logues thereof. Preferably, the detectable moiety is an enzyme and most preferably the enzyme is alkaline phos phatase.
As used herein, "solid phase material" means any material which is insoluble, or can be made insoluble by a subsequent reaction. Representative examples of solid phase materials include polymeric or glass beads, microparticles, tubes, sheets, plates, slides, wells, tapes, test tubes, or the like.
As used herein, "substrate" means a material that can be converted into a fluorescent compound, such as 4-methylumbelliferone, by an appropriate enzyme. The rate at which the fluorescent compound is formed is an indication of the quantity of enzyme present in the reaction mixture. When the enzyme is a detectable moiety, as in an enzyme immunoassay, the quantity of enzyme present is related to the quantity of analyte present in the test sample. Thus, the measurement of fluorescence can be used to determine to the quantity of analyte present in the test sample.
As used herein, "analyte" means the compound to be detected or measured. The analyte has at least one epitope or binding site.
As used herein, "rheumatoid factors' means autoantibod ies directed against human IgG. Rheumatoid factors most often belong to the IgM class. They are primarily found in patients suffering from rheumatoid arthritis and may inter fere in immunoassays by causing false positive results. Immunoassays particularly susceptible to interference from rheumatoid factors are indirect IgM assays in which a solid phase material coated with the specific antigen capture specific IgM antibodies. The IgM antibody-antigen complex is detected by an anti-human IgM enzyme conjugate.
As used herein, "Toxo IgM assay" means a qualitative method for the detection of T. gondii specific IgM antibodies in human serum and plasma (e.g., EDTA, heparin, or sodium citrate). As used herein. "Rubella IgM assay" means a qualitative method for the detection of rubella specific IgM antibodies in human serum and plasma (e.g., EDTA, heparin, or sodium citrate). In situations where primary infection is suspected, the optimum time for specimen collection has been reported to be 1 to 2 weeks after the onset of the rash.
In order to more clearly understand the significance and operation of the present invention, it is important to be aware of the nature of the immunoassays that can be run on an apparatus of the type described in U.S. Pat. No. 5,358,691, incorporated herein by reference. Many types of immunoas says can be run on an apparatus of the type described in U.S. Pat No. 5.358,691. In general, immunoassays can be clas sified into two major categories-homogeneous and hetero geneous. Homogeneous and heterogeneous immunoassays depend upon the ability of a first binding member of a binding member pair, e.g., an antigen, to specifically bind to a second binding member of a binding member pair, e.g., an antibody. A conjugate, comprising one of such binding members labeled with a detectable moiety, is employed to determine the extent of such binding. For example, such binding member pairs can be an antigen and an antibody to such antigen. The conjugate, which can comprise the antibody, either participates in a binding reaction with the antigen or does not participate in such a reaction. The amount of detectable moiety detected and measured after the reaction can be correlated to the amount of antibody present in the test sample.
Heterogeneous assays can be performed in a competitive immunoassay format or in a sandwich immunoassay format. In the competitive immunoassay format, an antigen can be immobilized to a solid phase material. The amount of detectable moiety that binds to the solid phase material can be detected, measured, and correlated to the amount of antibody present in the test sample. Examples of solid phase materials include beads, particles, microparticles, and the like.
The present invention is concerned primarily with the sandwich immunoassay format. In one example of the sandwich immunoassay format, a test sample containing an antibody is contacted with an antigen, e.g., a protein, that has been immobilized on a solid phase material, thereby forming an antigen-antibody complex. Examples of solid phase materials include beads, particles, microparticles, and the like. The solid phase material containing the antigen antibody complex is typically treated, for example, with a second antibody that has been labeled with a detectable moiety. The second antibody then becomes bound to the antibody of the sample, which is bound to the antigen immobilized on the solid phase material. Then, after one or more washing steps to remove any unbound material, an indicator material, such as a chromogenic substance, is introduced to react with the detectable moiety to produce a detectable signal, e.g., a color change. The color change is then detected, measured, and correlated to the amount of antibody present in the test sample. It should also be noted that various diluents and buffers are also required to opti mize the operation of the microparticles, antigens, conjugates, and other components of the assay that partici pate in chemical reactions. It should be further noted that other types of sandwich assays can be utilized, such as, for example, where the first antibody is immobilized on the solid phase material.
A heterogeneous immunoassay that can be performed with the apparatus of U.S. Pat. No. 5.358.691 in either a competitive or sandwich immunoassay format is a micro particle capture enzyme immunoassay, such as that 7 described in Clinical Chemistry, Volume 34, No. 9, pages 1726 -1732 (1988 , employing microparticles as the solid phase material. This article is incorporated herein by refer CCS.
A step-by-step description of a microparticle capture enzyme immunoassay procedure is set forth at col. 35, line 60 through col. 44, line 22 of U.S. Pat. No. 5.358,691.
One aspect of the method of the present invention can be conducted in the following manner. First, a biological sample is provided. Then, the sample is combined with a solid phase material having immobilized thereon a binding member specific for an antibody. An example of such a binding member is an antigen, e.g., rubella virus antigen, T. gondii antigen. Antibodies in the sample, if any, for which the immobilized binding member is specific, are allowed to bind to the immobilized binding member to form a binding member-antibody complex. Antibodies of particular interest in this invention include the IgM antibody to rubella virus antigen and the IgM antibody to T. gondii antigen. Then the solid phase material is separated from the sample, preferably by applying the mixture of solid phase material and sample to a porous matrix. The solid phase material is then washed on the matrix with a sufficient amount of a rheumatoid factor neutralization buffer, which buffer has a pH sufficiently low to cause rheumatoid factors, if present, to dissociate from IgG antibodies bound to the solid phase material. Then, it is preferred that any additional unbound materials be removed from the solid phase material by means of washing on the matrix, typically with a buffer, e.g., a neutral pH buffer. The solid phase material is then subjected to an antibody-enzyme conjugate that will bind to the binding member-antibody complex immobilized on the solid phase material. Then, unbound materials are removed from the solid phase mate rial by means of washing on the matrix, typically with a buffer, e.g., a neutral pH buffer. A substrate for the enzyme is added to the matrix. The rate of formation of detectable product, e.g., fluorescent product, is then measured and the level of IgM antibodies in the sample is determined. It should be noted that, the expression "IgG antibodies bound to the solid phase material", as used herein, is intended to include both (1) IgG antibodies attached directly to the solid phase material and (2) IgG antibodies bound to a binding member that is attached directly to the solid phase material.
The pH of the rheumatoid factor neutralization buffer must be sufficiently low to reduce, more preferably eliminate, the binding of rheumatoid factors to the immu nocomplexes consisting of IgG antibodies, e.g., anti-rubella IgG antibodies or anti-T. gondii IgG antibodies, bound to the solid phase material, but not so low that the binding of the IgM antibodies, e.g., anti-rubella IgM antibodies or anti-T. gondii IgM antibodies, bound to binding members, e.g., antigens, immobilized on the solid phase material is adversely affected. As a result of using a sufficient amount of rheumatoid factor neutralization buffer having an appro priately low pH, biological samples containing rheumatoid factors will not create false positive assay results in assays for IgM antibodies.
Another aspect of the method of the present invention can be conducted in the following manner. First, a biological sample is provided. Then a reagent comprising a solid phase material having immobilized thereon a binding member specific for an antibody of interest is provided. An example of such a binding member is an antigen, e.g., rubella virus antigen, T. gondii antigen. Then, the sample or the reagent or both sample and reagent is diluted in a sufficient amount of rheumatoid factor neutralization buffer, which buffer has a pH sufficiently low to prevent rheumatoid factors, if Then the solid phase material is separated from the sample, preferably by applying the mixture of solid phase material and sample to a porous matrix. Then, it is preferred that any unbound materials be removed from the solid phase material by means of washing on the matrix, typically with a buffer, e.g. a neutral pH buffer. The solid phase material is then subjected to an antibody-enzyme conjugate that will bind to the binding member-antibody complex. Then, unbound materials are removed from the solid phase material by means of washing on the matrix, typically with a buffer, e.g., a neutral pH buffer. A substrate for the enzyme is added to the matrix. The rate of formation of detectable product, e.g., fluorescent product, is then measured and the level of IgM antibodies in the sample is determined. As stated previously, the expression "IgG antibodies bound to the solid phase material", as used herein, is intended to include both (1) IgG antibodies attached directly to the solid phase material and (2) IgG antibodies bound to a binding member that is attached directly to the solid phase material.
The pH of the rheumatoid factor neutralization buffer must be sufficiently low to cause the pH of resulting reaction mixtures containing rheumatoid factors to reduce, more preferably prevent, the binding of rheumatoid factors to the immunocomplexes consisting of IgG antibodies, e.g., anti rubella IgG antibodies or anti-T. gondi IgG antibodies. bound to the solid phase material, but not so low that the binding of IgM antibodies, e.g., anti-rubella IgM antibodies or anti-T. gondii IgM antibodies, to binding members, e.g., antigens, on the solid phase material is adversely affected. As a result of using a sufficient amount of rheumatoid factor neutralization buffer having an appropriately low pH, bio logical samples containing rheumatoid factors will not cre ate false positive assay results in assays for IgM antibodies.
In either aspect, classes of buffers that are suitable for the method of this invention include ionic, nonionic, and zwit terionic buffers having a pKa value no higher than about 6.5. Additional details on the meaning of pH and pKa can be found in "Buffers-A guide for the preparation and use of buffers in biological systems". Donald E. Gueffroy, editor, Calbiochem-Novabiochem (1975) , incorporated herein by reference. Representative examples of buffers that are suit able for the method of this invention include, but are not limited to, acetic acid, citric acid, formic acid, succinic acid, and glycine.
Buffers that are suitable for the present invention prefer ably have a pH ranging from about 3.0 to about 6.5, more preferably from about 3.5 to about 5.5, most preferably from about 3.5 to about 5.0. If the pH of the rheumatoid factor neutralization buffer is too low, the binding members of interest will not bind to form complexes. If the pH of the rheumatoid factor neutralization buffer is too high, rheuma toid factors will bind to IgG antibodies bound to the solid phase material and yield false positive test results. It is also preferred that antimicrobial agents be included with the buffer.
During use, the rheumatoid factor neutralization buffer should be present in a concentration that will yield the appropriate level of pH. When the rheumatoid factor neu 5,698,393 9 tralization buffer is used to wash the binding member antibody complex on a solid phase material on a porous matrix, the pH of the buffer will not vary because the buffer will not be affected by the biological sample. If the rheu matoid factors are bound to a complementary binding member, such as IgG antibodies bound to the solid phase material, subjecting the complex containing the rheumatoid factors to a rheumatoid factor neutralization buffer having the appropriate pH will cause the complexes containing rheumatoid factors to break down, thereby allowing the unbound rheumatoid factors to be washed away. However, when the rheumatoid factor neutralization buffer is used in a mixture containing the biological sample, the biological sample can cause the pH of the mixture to vary. Accordingly, in this situation, it is desirable to rely on pKa values as a means of regulating the pH of the environment for elimi nating rheumatoid factors. If the rheumatoid factors in a sample are not bound to a complementary binding member, e.g., IgG antibodies bound to the solid phase material, maintaining the rheumatoid factors in an environment hav ing the appropriate pH will prevent them from binding to a complementary binding member.
Because suitable concentrations of the rheumatoid factor neutralization buffer can vary over a wide range, it is difficult to state the precise amount of rheumatoid factor neutraliza tion buffer needed for a given assay. In general, in the aspect wherein the solid phase material containing the binding member-antibody complex is washed, the amount of rheu matoid factor neutralization buffer required is dependent upon the surface area of the porous matrix. In the aspect wherein the sample or the reagent containing the solid phase material or both sample and reagent is diluted, the amount of rheumatoid factor neutralization buffer required is depen dent upon the dynamics of the assay protocol, e.g., reagent volumes. In IgMassays, e.g., the Toxo IgM assay and in the Rubella IgMassay run on the AxSYMC) instrument, suitable amounts of rheumatoid factor neutralization buffer and the pH thereof can be calculated by calibrating against known samples. Such calibration can be readily carried out by one of ordinary skill in the art.
The rheumatoid factor neutralization buffer can be intro duced in the assay procedure at any of several points. For example, the buffer can be introduced at the beginning of the procedure to an untreated biological sample or to a reagent containing a solid phase material to which is bound a specific binding member, e.g., an antigen, or to both sample and reagent. It is preferred to dilute the sample only. However, it is also possible to dilute the reagent only or to dilute both the sample and the reagent. Regardless of which component of the assay is diluted by the rheumatoid factor neutralization buffer, the principle of eliminating rheumatoid factors is the same. Of course, if the reagent only is diluted, elimination of rheumatoid factors from the sample will not occur until the sample is combined with the reagent. Alternatively, the buffer can be used to wash solid phase materials containing complexes comprising binding member pairs, e.g., antigen-antibody complexes, that have formed via the reaction of binding members in the sample, e.g. antibodies, with binding members attached to the solid phase material, e.g., antigens.
In the Toxo IgM assay and in the Rubella IgM assay false positive results are often caused by the presence of rheu matoid factors in human sera or plasma. For the Toxo IgM assay, rheumatoid factor neutralization buffer preferably at a pH of from about 4.0 to about 5.0 can be applied onto the matrix after the reaction mixture consisting of microparticles coated with T. gondii antigen and biological sample is For the Rubella IgM assay, rheumatoid factor neutraliza tion buffer preferably at a pH of from about 4.0 to about 5.0 can be applied onto the matrix after the reaction mixture consisting of microparticles coated with rubella virus anti gen and biological sample is applied to the matrix. Rheu matoid factors bound to anti-rubella IgG antibodies captured by the microparticles are eluted.
Alternatively, for either the Toxo IgMassay or the Rubella IgM assay, samples containing human sera or plasma or other biological fluids can be diluted with rheumatoid factor neutralization buffer prior to mixing the sample with the microparticles coated with the antigen of interest.
Turning now to details of the microparticle capture enzyme immunoassay typically used in the Toxo IgM assay and in the Rubella IgM assay, the presence of IgM antibod ies is measured by using a solid phase material having a binding member specific for IgM antibody of interest bound thereto. An example of a solid phase material is a micro particle coated with an antigen capable of binding with the specific antibody of interest. The sample is combined with the solid phase material to form a mixture; the mixture is incubated, whereby the antigen combines with the antibody of interest. The solid phase material and the test sample are separated so that the amount of IgM antibody bound to the antigen-coated solid phase material can be determined. The amount of IgM antibody bound to the solid phase material is preferably determined by enzyme immunoassay, wherein an anti-human IgM antibody labelled with an enzyme is used as the conjugate. A material referred to as an enzyme substrate can be converted into a fluorescent compound, such as 4-methylumbelliferone, by an appropriate enzyme.
The rate at which the fluorescent compound is formed is an indication of the quantity of enzyme present in the reaction mixture. When the enzyme is the detectable moiety, as in an enzyme immunoassay, the quantity of enzyme present is related to the quantity of conjugate present in the test sample. Thus, the measurement of fluorescence can be used to determine to the quantity of IgM antibody present in the test sample. The amount of anti-human IgM conjugate on the solid phase material can be correlated to the concentra tion of IgM antibody in the test sample by means of a plot showing enzyme activity as a function of concentration of IgM antibody, typically referred to as a standard curve. A standard curve can be prepared by performing the assay using calibrators, which are known to one having ordinary skill in the art. Alternatively, particularly in the case of assays for IgM antibodies, a single index calibrator is used to determine cutoff values for the assay. Controls are used to verify that the calibration is valid. When a sample having an unknown level of IgM antibody is assayed, the measured assay signal is compared to the index calibrator, and the index value level contresponding to the measured signal is the level of IgM antibody in the sample, A specific binding member may be bound to the solid phase by physical or chemical means, preferably by means of a covalent bond or by hydrophobic interaction. The specific binding member should be bound to the solid phase in such a way that substantially none of the specific binding members detach during the subsequent reactions and wash steps. Regardless of the specific binding member and the coupling method selected, the specific binding member must be able to bind to the IgM antibodies in the sample after being coupled to the solid phase material, A solid phase material according to the present invention may be a mixture of microparticles with binding members specific for the analyte of interest chemically or physically bound to the microparticles. Microparticles that can be used in this invention are preferably made of polymeric material, and more preferably include microparticles derived from polymers having styrene units or polymers having acrylate units. The microparticles are preferably substantially spheri cal and preferably have radii ranging from about 0.1 um to about 0.25 inches. A preferred method for separating these particles from the test sample involves capture of the micro particle on a porous matrix, such as a glass fiber.
A porous matrix suitable for use in this invention can be any suitable porous material. As used herein, "porous mate rial" means a material through which fluids can flow and can easily pass. Representative examples of materials suitable for the porous matrix include, but are not limited to, olefin polymers, e.g., polypropylene, polyethylene, fluorinated ole fin polymers, e.g., polytetrafluorethylene, fiberglass, cellulose, or nylon.
Preferred materials for the porous matrix include a porous fiberglass material, such as a "Whatman 934-AH" filter paper, which has a nominal thickness of 0.33 mm, or the disposable IMx& cartridge and TestPackTM (fiber matrix) As stated previously, an enzyme substrate can be con verted into a fluorescent compound, such as 4-methylumbelliferone, by an appropriate enzyme. The rate at which the fluorescent compound is formed is an indication of the quantity of enzyme present in the reaction mixture. When the enzyme is the detectable material, the quantity of enzyme present is related to the quantity of IgM antibodies present in the test sample. Thus, the measurement of fluo rescence resulting from enzyme activity in an enzyme immunoassay can be used to determine the quantity of IgM antibodies present in the test sample. Fluorescence can be measured by any method known to the art. For example, a fluorescence spectrometer can be used. The fluorescence spectrum can also be observed by means of a visual spec trometer or by a photograph with a spectrograph of high light-gathering power.
The following examples are illustrative of the invention and are not to be interpreted as limiting the scope of the invention, as defined in the claims. Initially, serum or plasma (10 L) was diluted at a 1:27 ratio with AxSYMS Line Diluent (0.1M phosphate buffer, pH 7.5) by the sampling probe. An aliquot containing diluted sample and AxSYMC& T. gondit Coated Microparticles (strain RH) was delivered to an incubation well of the reaction vessel to form a reaction mixture. The diluted sample was drawn from a dilution well and the coated microparticles were drawn from areagent pack. The reaction mixture was incubated for approximately eight (8) The matrix cell was washed to remove unbound materials.
Goat anti-human IgM antibody:alkaline phosphatase con jugate (25 L at a concentration of 1 g/mL in conjugate buffer (0.5M Tris, 5% mouse serum, pH 7.2)) was dispensed onto the matrix cell and the resultant combination was incubated for approximately eight (8) A solution of the substrate, 4-methylumbelliferyl phos phate (MUP) in aminomethyl phosphate buffer (1.2 mM), was added to the matrix cell, and the rate of formation of 4-methylumbelliferone was measured by fluorescence reflectance. Fluorescent product, 4-methylumbelliferone, was measured by the microparticle enzyme immunoassay (MEA) optical assembly of the AxSYMC) instrument.
The AxSYMS) system calculated an Index Value for the Toxo IgM assay based on the ratio of the Sample Rate to the Index Calibrator Mean Rate for each sample and control.
Index Value=Sample Rate/Index Calibrator Mean Rate The aforementioned rates are based on rate of formation of fluorescent product, typically measured in counts per second per second. Samples having an Index Value lower than 0.500 were considered to be negative for IgM antibodies to T. gondii by the criteria of the AxSYMS Toxo IgM assay. Samples having an Index Value of from 0.500 to 0.599 were considered equivocal. Samples interpreted as equivocal may contain very low levels of IgM. Samples having an Index Value equal to or greater than 0.600 were considered to be positive for IgM antibodies to T. gondii antigen by the criteria of the AxSYM6 Toxo IgM assay.
Materials needed for the assay, including AxSYMO) RF The Toxo gondii IgM assay was performed on the IMx6 instrument according to the manufacturer's instructions (catalog no. 7A82-20). The purpose for using this format is to show that the assay of the present invention performs equal to or better than a well-known assay in the art.
This analyzer contains an optical assembly comprising a fluorometer that uses a mercury arc lamp as its light source. This instrument is described by Fiore et al (Clin. Chem., 34/9:1726 -1732 , 1988 , incorporated herein by reference. The instrument utilizes IMx6) disposable cartridges (commercially available from Abbott Laboratories. Abbott Park, Ill.), which contain a porous matrix to capture micro particles containing complexes resulting from the reaction of antigens with antibodies from the sample. The bound IgM antibodies are then detected with the goat anti-human IgM:enzyme conjugate. The label used in the conjugate is preferably alkaline phosphatase. The microparticles are separated from the reaction mixture, conjugate is added to the microparticles, conjugate binds to available IgM antibodies, and the quantity of conjugate present on the microparticles is determined from the rate at which 4-methylumbelliferyl phosphate is converted into 4-methylumbelliferone. The quantity of IgM antibodies in the sample can be determined from a standard curve of rate of 4-methylumbelliferone formation as a function of IgM antibody concentration.
The index calibrator that relates the rate of formation of 4-methylumbelliferone to IgM antibody concentration is similar to that described for the AxSYMCS Toxo IgM assay. One of ordinary skill in the art would be capable of devising calibrator and control formulations suitable for the IMx8 Toxo IgM assay.
In brief, a serum or plasma sample was diluted at a 1:30 ratio with IMxGMEIAbuffer (0.5M Tris, pH 7.5) and mixed with T. gondii Coated Microparticles. The reaction mixture was incubated for approximately eight (8) minutes at a temperature of 35° C.
An aliquot of the microparticles containing the antigen antibody complex was transferred to the matrix cell of the IMx6) instrument. The microparticles bound irreversibly to the glass fiber matrix of the matrix cell. The matrix cell was washed to remove unbound materials.
Goat anti-human IgM antibody:alkaline phosphatase con jugate (25 L at a concentration of 1 pg/mL in conjugate buffer (0.5M Tris, 5% mouse serum, pH 7.2)) was dispensed onto the matrix cell and the resultant combination was incubated for approximately eight (8) minutes at a tempera ture of 35° C. The matrix cell was washed to remove unbound materials.
A solution of the substrate, 4-methylumbelliferyl phos phate (MUP) in aminomethyl phosphate buffer (1.2 mM), was added to the matrix cell, and the rate of formation of 4-methylumbelliferone was measured by fluorescence reflectance. Fluorescent product, 4-methylumbelliferone, was measured by the microparticle enzyme immunoassay (MEIA) optical assembly of the IMxG) instrument.
The IMx6 System calculated an Index Value for the Toxo IgM assay based on the ratio of the Sample Rate to the Index Calibrator Mean Rate for each sample and control. The aforementioned rates are based on rate of formation of fluorescent product, typically measured in counts per second per second. Samples having an Index Value less than 0.500 were considered to be negative for IgM antibodies to T. gondii antigen by the criteria of IMx8 Toxo IgM assay.
Samples having an Index Value ranging from 0.500 to 0.599 were considered equivocal. Samples interpreted as equivo cal may contain very low level of IgM. Samples having an Index Value equal to or greater than 0.600 were considered to be positive for IgM antibodies to T. gondi antigen by the criteria of IMx6 Toxo IgM assay.
All positive and equivocal specimens, i.e., those having an Index Value greater than 0.500, were treated with the IMx(E) Rheumatoid Factor Neutralization Reagent (human IgG coated microparticles; catalog no. 1A14-22) and Reagent. The results of the tests using the rheumatoid factor neutralization buffer with the AxSYMCE) instrument are set forth in Table I . The data in Table I demonstrate that with an index cut-off for positive samples of 0.600, the pH range for the citrate buffer that was most effective in preventing rheumatoid factor interference was pH 4.0 to pH 5.0. The only sample that was positive for IgM antibodies to T. gondii antigen was the PC sample. The four rheumatoid factor positive samples . In addition, the samples were evaluated by the AxSYMS Toxo IgM assay. Table II shows the Index Values obtained for the sample set. with rheumatoid factor positive specimens to create false positive specimens for the IMx5) Toxo IgM assay. In addition, the rheumatoid factor neutralization buffer (pH 4.5) that was used in the AxSYMO) Toxo IgM assay was substituted with the MEIA buffer (pH 7.5) that was used in the IMx Toxo IgM assay. These samples were evaluated and the results are shown in Table II . The results of this experiment demonstrated that the wash with pH 4.5 buffer eluted the rheumatoid factors, but the wash with pH 7.5 buffer did not elute the rheumatoid factors. Thus, the low pH rheumatoid factor neutralization buffer helped to minimize the number of false positive test results. No. 5.358, 691) . Further pipetting was carried out in the processing center at the processing probe (see second trans fer pipette mechanism 50 of U.S. Pat. No. 5, 358, 691) .
Serum or plasma was diluted at a 1:30 ratio in rheumatoid factor neutralization buffer (AxSYMO RF Neutralization Buffer, 0.5M citrate, pH 4.5) by the sampling probe. An aliquot of diluted sample and AxSYMCS) Rubella Virus Coated Microparticles (strain HPV 77) was delivered to an incubation well of the reaction vessel to form a reaction mixture. The diluted sample was drawn from a dilution well and the coated microparticles were drawn from a reagent pack. The reaction mixture was incubated for approximately eight (8) minutes at a temperature of 35° C.
AxSYMS Assay Diluent (0.5M Tris, 25% calf serum, pH 7.5) was added to the reaction mixture and an aliquot of the microparticles containing antigen-antibody complex was transferred to the matrix cell of the AxSYM) instrument.
The microparticles bound irreversibly to the glass fiber matrix of the matrix cell. The matrix cell was washed with AxSYMCS) Line Diluent (0.1M phosphate buffer, pH 7.2) to remove unbound materials.
Goat anti-human IgM antibody:alkaline phosphatase con jugate (25 L at a concentration of 1 g/mL in conjugate buffer (0.5M Tris, 5% fetal calf serum, pH 7.2)) was dispensed onto the matrix cell and incubated for approxi mately eight (8) minutes at a temperature of 35° C. The matrix cell was washed to remove unbound materials.
A solution of the substrate, 4-methylumbelliferyl phos phate in aminomethyl phosphate buffer (1.2 mM, 50 L), was added to the matrix cell, and the rate of formation of 4-methylumbelliferone was measured by fluorescence reflectance. Fluorescent product, 4-methylumbelliferone, was measured by the MELA optical assembly.
The AxSYMCS System calculated a Rubella IgM Index Value based on the ratio of the sample rate to the Index Calibrator Mean Rate for each sample and control.
Index Value=Sample Rate/Index Calibrator Mean Rate The aforementioned rates are based on rate of formation of fluorescent product, typically measured in counts per second per second. Samples having an Index Value less than 0.600 were considered to be negative for IgM antibodies to rubella virus antigen by the criteria of AxSYMS Rubella IgM assay.
Samples having an Index Value of from 0.600 to 0.799 were considered equivocal. Samples interpreted as equivocal may contain very low levels of Rubella IgM. Samples having an Index Value equal to or greater than 0.800 were considered to be positive for IgM antibodies to rubella virus antigen by the criteria of AxSYMS Rubella IgM assay and may be indicative of primary rubella infection.
Materials needed for the assay, including AxSYMCs) RF Neutralization Buffer (citrate and containing antimicrobial agents), AxSYMS) Assay Diluent (buffer with protein sta bilizers and containing antimicrobial agents), AXSYMCS Rubella Virus Coated Microparticles (in buffer with protein stabilizers and containing antimicrobial agents), Anti Human IgM (goat):Alkaline Phosphatase Conjugate (in buffer with protein stabilizers and containing 0.1% sodium azide), 4-methylumbelliferyl phosphate substrate (1.2 mM, in buffer and containing 0.1% sodium azide), AxSYMC) Line Diluent (0.1M phosphate buffer and containing anti microbial agents), AxSYM6) instruments and commodities are available commercially from Abbott Laboratories, Abbott Park, .
IMx9 Assay Format The Rubella Virus IgM assay was performed on the IMx6 instrument according to the manufacturer's instructions . Operation of the instrument was described previously in Example 1. The purpose for using this format is to show that the assay of the present invention performs equal to or better than a well-known assay in the art In brief, a serum or plasma sample was diluted at a 1:10 ratio with IMxGMEIA assay buffer (0.5M Tris, pH 7.5) and mixed with the AxSYMS Rubella Virus Coated Micropar ticles (strain HPV 77) to form a reaction mixture. The reaction mixture was incubated for approximately eight (8) minutes at a temperature of 35° C.
An aliquot of the microparticles containing the antigen antibody complex was transferred to the matrix cell of the IMx(s) instrument. The microparticles bound irreversibly to the glass fiber matrix of the matrix cell. The matrix cell was washed to remove unbound materials.
Goat anti-human IgM antibody:alkaline phosphatase con jugate (2.5 L at a concentration of 1 g/mL in conjugate buffer (0.5M Tris, 25% fetal calf serum, pH 7.2)) was dispensed onto the matrix cell and the resultant combination was incubated for approximately eight (8) minutes at a temperature of 35° C. The matrix cell was washed to remove unbound materials.
A solution of the substrate, 4-methylumbelliferyl phos phate (MUP) in aminomethyl phosphate buffer (1.2 mM), was added to the matrix cell, and the rate of formation of 4-methylumbelliferone was measured by fluorescence reflectance. Fluorescent product, 4-methylumbelliferone, was measured by the microparticle enzyme immunoassay (MELA) optical assembly of the IMxos instrument.
The IMx System calculated a Rubella Virus Index Value based on the ratio of the sample rate to the Index Calibrator Mean Rate for each sample and control.
Index Wahue=Sample Rate/Index Calibrator Mean Rate The aforementioned rates are based on rate of formation of fluorescent product, typically measured in counts per second per second. Samples having an Index Value less than 0.800 were considered to be negative for IgM antibodies to rubella virus antigen by the criteria of IMx8 Rubella IgM assay. Samples having an Index Value of 0.800 to 0.999 were considered to be equivocal. Samples interpreted as equivo cal might contain very low level of Rubella IgM antibodies. Samples having an Index Value equal to or greater than 1.000 were considered to be positive for IgM antibodies to rubella virus antigen by the criteria of IMx Rubella IgM assay and might be indicative of primary rubella infection.
All positive and equivocal samples, i.e., those having an Index Value greater than or equal to 0.800, were treated with the IMx. Rheumatoid Factor Neutralization Reagent (human IgG coated microparticles; catalog no. 1A14-22) and retested.
Results

Buffer pH Optimization
Citrate buffers at pH values varying from pH 3.5 to pH 5.5 and phosphate buffer at pH 7.5 were prepared and evaluated Table  IV . The data in Table IV demonstrate that with an index cut-off for positive samples of 0.600, the pH range for the citrate buffer that was most effective in preventing rheuma toid factor interference was pH 3.5 to pH 5.0. The only sample that was positive for IgM antibodies to rubella virus antigen was the IgM Positive Sample. The three rheumatoid factor positive samples (RFP4, RFFY3, and RFFY4) were correctly identified as negative for IgM antibodies to rubella virus antigen when the pH of the buffer was no higher than pH 5.0, 2. Sample Evaluation A. Clinical Rheumatoid Factor Samples. One hundred fifty seven (157) rheumatoid factor positive clinical samples were evaluated on the IMx(8) assay format and the AxSYMO) Rubella IgM assay format. In addition, the rheumatoid factor neutralization buffer (pH 4.5) used in the AxSYMC Rubella IgM assay was substituted with the MEIA buffer (pH 7.5) used in the IMx& Rubella IgM assay. Thirty six (36) samples were rheumatoid factor positive or equivocal and were retested on the IMx(8 Rubella IgM assay after treatment with IMxG) Rheumatoid Factor Neutraliza tion Reagent (human IgG coated microparticles; catalog no. 1A14-22) . In order to demonstrate the efficacy of the low pH AxSYMS Rubella IgM assay format, the 36 samples were also evaluated on the AxSYMO) Rubella IgM assay format using the MEIA buffer (pH 7.5) for diluting the sample. The results of this evaluation demonstrated that diluting the samples in rheumatoid factor neutralization buffer hav ing pH of 4.5 eliminated the false positive reaction that would be expected with samples containing rheumatoid factors. Use of the MEA buffer in the AxSYM) Rubella IgM assay yielded results similar to those obtained with the IMx(S) Rubella IgM assay that did not utilize rheumatoid factor neutralization with IMx03) Rheumatoid Factor Neu tralization Reagent (human IgG coated microparticles; cata log no. 1A14-22).
Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention, and it should be understood that this invention is not to be unduly limited to the illustrative embodiments set forth herein.
What is claimed is:
